LETTER TO THE EDITOR

Delayed cancer diagnoses and high mortality in children during the COVID-19 pandemic

To the Editor,

Although the effects of the SARS-CoV-2 virus on infected patients are increasingly documented, the indirect consequences for uninfected patients are less well described. We report five cases of children who presented critically ill to two U.S. tertiary referral centers (Children’s Hospital of Philadelphia [CHOP] and Lucile Packard Children’s Hospital at Stanford [LPCH]) in April 2020. All patients tested SARS-CoV-2 negative and experienced delays in cancer diagnosis due to the COVID-19 pandemic with grave consequences.

Each patient required emergent life-saving interventions shortly after presentation (Table 1), including resuscitation following cardiac arrest (N = 2), emergent intubation (N = 4), and emergent pericardiocentesis for tamponade (N = 1). Two patients died within days of presentation. Although pediatric cancers can present with severe initial findings, the clustered frequency and acuity of these recent initial presentations is striking.

Coinciding with the rapid rise in regional COVID-19 cases and initiation of stay-at-home orders, both institutions noted significant changes in the timing and severity of new patient presentations. The first COVID-19 case in Pennsylvania was reported on March 6, 2020. Despite a five-year historical mean of 2.96 days between new leukemia patients, CHOP did not see any patients with a new leukemia diagnosis for 35 days (March 2, 2020, to April 6, 2020). Comparatively, the longest gap from 2015 to 2019 was 18 days. Thus, it was notable when two patients subsequently diagnosed with acute lymphoblastic leukemia (ALL) presented on consecutive days to the pediatric intensive care unit (PICU) after having cardiac arrests at local hospitals in April. Similarly, LPCH noted an increase in the percentage of patients requiring prolonged PICU care at diagnosis. In April 2020, 75% of new leukemia/lymphoma diagnoses required PICU care, compared with a historic monthly average of 12% during 2018–2019 (previous maximum 40%).

Pediatric cancers are relatively rare, and thus delays in diagnosis can occur. However, our experience suggests that additional factors specific to the ongoing COVID-19 pandemic contributed to care delays and higher patient acuity. The family of one patient expressed reluctance to seek care due to fear of COVID-19 exposure. The other four patient families had repeated contact with the healthcare system prior to ultimate diagnosis. This suggests that healthcare system factors may play a role, including decreased referrals to emergency departments or laboratories, and transition to alternative evaluation methods such as telemedicine. Diagnostic bias may also occur, since presenting signs of malignancy (fever, malaise, and respiratory symptoms) can initially be mistaken for symptoms of COVID-19. Furthermore, endemic areas have reported that children are less likely to become critically ill from COVID-19 disease as compared with adults, which may delay referral of children for emergency services or laboratory studies.

Two patients had multiple telehealth visits prior to in-person evaluations. Telemedicine utilization among primary and acute care providers is increasing during the pandemic. The limitations of telemedicine, including lack of ability to detect critical physical exam findings such as unstable vital signs, pallor, and hepatosplenomegaly, are underscored by these cases. For example, after two telehealth visits and one visual assessment outside the primary care provider’s office, patient 1 re-presented hours later to a local emergency department with overwhelming sepsis that progressed to cardiac arrest and brain death. Such an outcome is particularly difficult given the extremely favorable prognosis of childhood ALL. Indeed, the pediatric cancer diagnoses presented here are highly curable in North America with expected cure rates ranging from 67% to over 95% depending on diagnosis.

These cases illustrate the indirect impact of this pandemic on morbidity in COVID-19–negative patients for whom care delays can be fatal. We highlight the unintended consequences of a pandemic-transformed healthcare system for a vulnerable pediatric population. More work is critical to quantify these consequences and to develop solutions that protect severely ill but treatable children, while also balancing public health and the needs of those infected during this COVID-19 pandemic.

FUNDING SOURCE
No specific support for this project.

CONFLICTS OF INTEREST
The authors have no conflicts of interest/financial relationships relevant to this article to disclose.

ORCID
Yang-Yang Ding https://orcid.org/0000-0003-1588-2571
Charles A. Phillips https://orcid.org/0000-0002-0391-1673
Susan R. Rheingold https://orcid.org/0000-0001-8025-6767
**TABLE 1**  Clinical characteristics, presentation, and outcomes of children who presented in critical condition and were subsequently diagnosed with cancer

| Patient | Age (years) | Sex | Symptoms at presentation | Onset of symptoms | Tele-health | PMD/urgent care | ED | Presumed diagnosis | Time from initial presentation to diagnosis | Oncologic diagnosis | SARS-CoV-2 RT-PCR assay | Notable laboratory/radiologic findings | Clinical course | Survival status |
|---------|-------------|-----|--------------------------|-------------------|------------|----------------|-----|-------------------|----------------------------------|-----------------|----------------------|------------------------------------|-----------------|-----------------|
| 1       | 4           | F   | Fevers, emesis, hallucinations | 3 weeks           | 2          | 1              | 1   | Viral syndrome    | 2 weeks                          | B-cell ALL      | Negative × 2          | WBC 1000/μL blasts 1.6% Hgb 2.3 g/dL Platelets 3,000/μL Lactate 13 mmol/L Uric acid 19 mg/dL Blood culture positive for Group G strep Many clusters of bacterial organisms on BMA | Presented in shock. Cardiac arrest with multisystem organ failure. Brain herniation. Hemodialysis delayed due to COVID-19-related staffing shortages. | Deceased (HD 5) |
| 2       | 16          | M   | Fevers, cough, emesis, diarrhea, dyspnea | 4.5 weeks         | 0          | 1              | 2   | Asthma flare and acute otitis media | 4 weeks                          | B-cell ALL      | Negative × 3          | WBC 1000/μL blasts 26% Hgb 3 g/dL Platelets 77,000/μL Lactate 15 mmol/L Uric acid 11.5 mg/dL | Presented in respiratory distress. Cardiac arrest with multisystem organ failure. Small cerebral hemorrhages. | Alive |
| 3       | 17          | F   | Abdominal pain, cough, palpitations | 2.5 weeks         | 4          | 0              | 1   | Gastritis         | 2 weeks                          | Stage III DLBCL | Negative × 1          | Echocardiogram: large circumferential pericardial effusion with right atrial and ventricular collapse. CT chest: large anterior mediastinal mass | Presented in cardiac tamponade. 1.5 L malignant pericardial fluid emergently drained. | Alive |
| 4       | 10          | F   | Shortness of breath, lethargy and cyanosis | 3 days            | Reported parental reluctance to present to care | 3 days | T-cell lymphoblastic lymphoma | Negative × 2 | pH of 6.9 pCO2 100 Lactate of 9.2 CT chest: large anterior mediastinal mass | Presented in respiratory distress and obtunded. Emergently intubated | Alive |
| 5       | 8           | M   | Fevers, throat pain, pallor, bruising, vomiting, fatigue, and eye pain | 4 weeks           | 0          | 2              | 0   | Tonsillitis       | 4 weeks                          | AML             | Negative × 1          | WBC 365,000/μL blasts 89% Hgb 6.1 g/dL Platelets 28,000/μL INR 1.7 Fibrinogen 191 | Presented with altered mental status. Status epilepticus and emergent intubation. Intracranial hemorrhage and herniation. | Deceased (HD 5) |

AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; BMA, bone marrow aspirate; DLBCL, diffuse large b-cell lymphoma; ED, emergency department; EMS, emergency medical services; HD, hospital day; Hgb, hemoglobin; PMD, primary medical doctor; WBC, white blood cell.
LETTER TO THE EDITOR

Yang-Yang Ding1
Sneha Ramakrishna2∗
Adrienne H. Long2
Charles A. Phillips1∗
Raul Montiel-Esparza2
Caroline J. Diorio1
L. Charles Bailey1
Shannon L. Maude1
Richard Aplenc1
Vandana Batra1
Anne F. Reilly1
Susan R. Rheingold1
Norman J. Lacayo2
Kathleen M. Sakamoto2
Stephen P. Hunger1

∗Y. Ding and S. Ramakrishna contributed equally as co-first authors to this manuscript.

REFERENCES

1. Lazzerini M, Barbi E, Apicella A, Marchetti F, Cardinale F, Trobia G. Delayed access or provision of care in Italy resulting from fear of COVID-19. Lancet Child Adolesc Heal. 2020;4(5):e10-1.
2. Ahrensberg JM, Olesen F, Hansen RP, Schrøder H, Vedsted P. Childhood cancer and factors related to prolonged diagnostic intervals: a Danish population-based study. Brit J Cancer. 2013;108(6):1280-1287.
3. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics. 2020:e20200702.
4. Hollander JE, Carr BG. Virtually perfect? Telemedicine for Covid-19. New Engl J Medicine. 2020;382:1679-1681.
5. Surveillance, Epidemiology, and End Results (SEER) Program (seer.cancer.gov). Accessed April 30, 2020.

Correspondence
Yang-Yang Ding, Children’s Hospital of Philadelphia, 3501 Civic Center Boulevard, CTRB 4020, Philadelphia, PA 19104.
Email: dingy@email.chop.edu

1Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
2Lucile Packard Children’s Hospital Stanford, Palo Alto, California